Trial reportClinical and experimental nephrology2013
Effect of allopurinol on cardiovascular incidence among hypertensive nephropathy patients: the Gonryo study.
Trial report in Clinical and experimental nephrology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 38 citations in OpenAlex.
- Xanthine oxidase inhibitors are associated with reduced risk of cardiovascular disease.Scientific reports · 2021Trial
- Trial
- Major adverse cardiovascular events and hyperuricemia as an effect-modifying factor in kidney transplant recipients.World journal of transplantation · 2025Article
- Comparison of the incidence of proteinuria and changes in eGFR among febuxostat and topiroxostat users.Clinical and experimental nephrology · 2025Article
- Association between serum uric acid and all-cause and cardiovascular-related mortality in hemodialysis patients.Frontiers in nutrition · 2024Article
- Clinical Significance of Elevated Xanthine Dehydrogenase Levels and Hyperuricemia in Patients with Sepsis.International journal of molecular sciences · 2023Article
- Association of serum xanthine oxidase levels with hypertension: a study on Bangladeshi adults.Scientific reports · 2022Article
- Different clinical impact of hyperuricemia according to etiologies of chronic kidney disease: Gonryo Study.PloS one · 2021Article
- Hyperuricemia in Kidney Disease: A Major Risk Factor for Cardiovascular Events, Vascular Calcification, and Renal Damage.Seminars in nephrology · 2020Review
- Are Doctors the Best People to Manage Gout? Is There a Role for Nurses and Pharmacists?Current rheumatology reports · 2018Review
- Relationship between Xanthine Oxidoreductase Redox and Oxidative Stress among Chronic Kidney Disease Patients.Oxidative medicine and cellular longevity · 2018Article
- Allopurinol use and the risk of acute cardiovascular events in patients with gout and diabetes.BMC cardiovascular disorders · 2017Article
- Allopurinol and the risk of stroke in older adults receiving medicare.BMC neurology · 2016Article
- Uric acid in metabolic syndrome: From an innocent bystander to a central player.European journal of internal medicine · 2016Review
- Effects of xanthine oxidase inhibitors on cardiovascular disease in patients with gout: a cohort study.The American journal of medicine · 2015Article
- Risk of incident diabetes in patients with gout: a cohort study.Arthritis & rheumatology (Hoboken, N.J.) · 2015Article
- Neutrophil gelatinase-associated lipocalin levels associated with cardiovascular disease in chronic kidney disease patients.Clinical and experimental nephrology · 2014Article
- Uric acid levels predict future blood pressure and new onset hypertension in the general Japanese population.Journal of human hypertension · 2014Observational
- Reactive oxygen species, vascular Noxs, and hypertension: focus on translational and clinical research.Antioxidants & redox signaling · 2014Review
- Uric Acid - key ingredient in the recipe for cardiorenal metabolic syndrome.Cardiorenal medicine · 2013Review
Corrections and comments
- Erratum issued
Authors and funding
12 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe present study aimed to clarify the beneficial effect of allopurinol on cardiovascular morbidity and mortality in a cohort of hypertensive nephropathy patients with impaired kidney function.
methodsOne hundred and seventy-eight patients diagnosed with hypertensive nephropathy and presenting with impaired kidney function (estimated glomerular filtration rate <45 mL/min/1.73 m(2)) were recruited from nephrology clinics. Oral allopurinol was prescribed in 67 of these patients. The effects of allopurinol use on the development of cardiovascular disease (i.e. ischemic heart disease, congestive heart failure, and stroke) and all-cause death was analyzed using the Cox proportional hazard model.
resultsDuring the follow-up of 18.4 months (mean), 28 primary events occurred. Basal use of allopurinol was a significant beneficial factor (hazard ratio = 0.342, p = 0.0434, standard error = 0.53058) after adjusting for confounding factors.
conclusionThe use of allopurinol in hypertensive subjects with impaired kidney function appears to be beneficial in preventing cardiovascular morbidity and all-cause mortality, indicating that this xanthine oxidase inhibitor protects the vascular system, at least in this specific group.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.